DK0637959T3 - Opløselige probucolanaloger - Google Patents

Opløselige probucolanaloger

Info

Publication number
DK0637959T3
DK0637959T3 DK93910932T DK93910932T DK0637959T3 DK 0637959 T3 DK0637959 T3 DK 0637959T3 DK 93910932 T DK93910932 T DK 93910932T DK 93910932 T DK93910932 T DK 93910932T DK 0637959 T3 DK0637959 T3 DK 0637959T3
Authority
DK
Denmark
Prior art keywords
chamber
tray
test strip
reaction vessel
fluid conduit
Prior art date
Application number
DK93910932T
Other languages
Danish (da)
English (en)
Inventor
Sampath Parthasarathy
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Application granted granted Critical
Publication of DK0637959T3 publication Critical patent/DK0637959T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Materials For Medical Uses (AREA)
DK93910932T 1992-04-30 1993-04-30 Opløselige probucolanaloger DK0637959T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/876,557 US5262439A (en) 1992-04-30 1992-04-30 Soluble analogs of probucol
PCT/US1993/004071 WO1993021914A1 (en) 1992-04-30 1993-04-30 Soluble analogs of probucol

Publications (1)

Publication Number Publication Date
DK0637959T3 true DK0637959T3 (da) 2002-12-23

Family

ID=25368007

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93910932T DK0637959T3 (da) 1992-04-30 1993-04-30 Opløselige probucolanaloger

Country Status (12)

Country Link
US (1) US5262439A (de)
EP (2) EP1161946A3 (de)
JP (1) JP3179494B2 (de)
AT (1) ATE222490T1 (de)
AU (1) AU4225493A (de)
CA (1) CA2134679C (de)
CY (1) CY2426B1 (de)
DE (1) DE69332220T2 (de)
DK (1) DK0637959T3 (de)
ES (1) ES2181688T3 (de)
PT (1) PT637959E (de)
WO (1) WO1993021914A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
AU2006202461B2 (en) * 1997-05-14 2009-12-03 Atherogenics, Inc. Compositions and methods for the inhibition of the expression of VCAM-1
AU2002300328B2 (en) * 1997-05-14 2006-04-13 Atherogenics, Inc Compounds and methods for the inhibition of the expression of VCAM-1
EP1468989A3 (de) * 1997-05-14 2008-12-03 Atherogenics, Inc. Verbindungen und Methoden zur Hemmung der VCAM-1 Expression
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
NZ528906A (en) 1997-05-14 2005-06-24 Atherogenics Inc Compounds and methods for the inhibition of the expression of VCAM-1
EP1695959A1 (de) * 1997-05-14 2006-08-30 Atherogenics, Inc. Verbindungen und Methoden zur Hemmung der VCAM-1 Expression
EP1607089A1 (de) * 1997-05-14 2005-12-21 Atherogenics, Inc. Monoester von Probucol zur Behandlung von kardiovaskulären Krankheiten und Entzündungskrankheiten
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
CN1261803A (zh) * 1997-07-01 2000-08-02 埃瑟若詹尼克斯公司 抗氧化剂增强对细胞过度增生性疾病的治疗
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6887712B1 (en) * 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
JP2003530383A (ja) * 2000-04-11 2003-10-14 アセロジエニクス・インコーポレイテツド 血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌ機能性を向上させる化合物および方法
US6323359B1 (en) * 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
AUPQ872800A0 (en) * 2000-07-12 2000-08-03 Heart Research Institute, The Compositions and methods for treating cardiovascular disorders
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP4334233B2 (ja) * 2001-04-11 2009-09-30 アセロジエニクス・インコーポレイテツド プロブコールモノエステルによって血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌの機能性を改善するための方法
US6651862B2 (en) 2001-04-30 2003-11-25 Illinois Tool Works Inc. Trim-type fastener driving tool
CA2464717A1 (en) * 2001-10-25 2003-05-15 Atherogenics, Inc. Compounds and methods for treating transplant rejection
IL161741A0 (en) * 2001-11-09 2005-11-20 Atherogenics Inc Methods of reversing and preventingcardiovascular pathologies
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
AU2003253887A1 (en) * 2002-07-12 2004-02-02 Atherogenics, Inc. Novel salt forms of poorly soluble probucol esters and ethers
AU2003266165A1 (en) * 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
MXPA05007548A (es) * 2003-01-13 2005-10-20 Atherogenics Inc Procedimiento para preparar esteres y eteres de probucol y derivados del mismo.
CH696357A5 (de) * 2003-02-14 2007-05-15 Siegfried Ltd Verfahren zur Herstellung von Probucolverbindungen.
GB0321613D0 (en) * 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
US20060025481A1 (en) * 2004-02-09 2006-02-02 Strange Matthew L Process for preparation of probucol derivatives and polymorphic forms thereof
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US7294737B2 (en) * 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
AU2005262390B2 (en) * 2004-07-01 2011-09-22 Atherogenics, Inc. Compounds and methods for treating diabetic vascular diseases
EP1844009A4 (de) * 2004-12-17 2010-04-21 Roland O Stocker Zusammensetzungen und verfahren zur behandlung von herzkreislauferkrankungen
US20060194981A1 (en) * 2005-02-26 2006-08-31 Jass Paul A Process for preparation of probucol derivatives
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
CA2606414A1 (en) * 2005-04-21 2006-11-02 Atherogenics, Inc. Process for the separation of probucol derivatives
EP1776970A1 (de) * 2005-10-12 2007-04-25 Albert Schömig Implantat mit Mehrfachbeschichtung
EP1916006A1 (de) * 2006-10-19 2008-04-30 Albert Schömig Wachs oder Harz beschichtetes Implantat
EP1913960A1 (de) 2006-10-19 2008-04-23 Albert Schömig Beschichtetes Implantat
BRPI0809423A2 (pt) * 2007-03-26 2014-09-09 Salutria Pharmaceuticals Llc Usos e composições de derivados de probucol para o tratamento de diabetes
US20080280985A1 (en) * 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
JP2010531354A (ja) * 2007-06-26 2010-09-24 アストラゼネカ アクチボラグ カルボキシ基で一置換されたプロブコール誘導体の単離方法
US20170224647A1 (en) * 2014-08-04 2017-08-10 Universita 'Degli Studi Parma New mdr1 inhibitors for overcoming multidrug resistance
CN106905208B (zh) * 2017-02-27 2018-09-07 江西瑞雅药业有限公司 普罗布考前药及其制备方法和药物组合物
CN108299263B (zh) 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 一种普罗布考衍生物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485843A (en) * 1967-05-11 1969-12-23 Dow Chemical Co Piperazine adducts of ketone mercaptoles
US3862332A (en) * 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
FR2130975A5 (en) * 1971-03-29 1972-11-10 Aries Robert Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics
FR2133024A5 (en) * 1971-04-06 1972-11-24 Aries Robert Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity
FR2168137A1 (en) * 1972-01-17 1973-08-31 Dynachim Sarl Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities
DE3442639A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
US4719237A (en) * 1986-01-28 1988-01-12 Merrell Dow Pharmaceuticals Inc. Cardiac antiarrythmic method employing probucol
US4985465A (en) * 1989-07-14 1991-01-15 Hendler Sheldon S Method for inhibiting viral and retroviral infections

Also Published As

Publication number Publication date
US5262439A (en) 1993-11-16
EP1161946A2 (de) 2001-12-12
EP1161946A3 (de) 2003-12-10
CA2134679C (en) 2003-11-25
EP0637959A1 (de) 1995-02-15
JPH07506373A (ja) 1995-07-13
ES2181688T3 (es) 2003-03-01
AU4225493A (en) 1993-11-29
WO1993021914A1 (en) 1993-11-11
CY2426B1 (en) 2004-11-12
ATE222490T1 (de) 2002-09-15
DE69332220D1 (de) 2002-09-26
DE69332220T2 (de) 2003-05-08
CA2134679A1 (en) 1993-11-11
PT637959E (pt) 2002-12-31
EP0637959A4 (de) 1995-03-29
JP3179494B2 (ja) 2001-06-25
EP0637959B1 (de) 2002-08-21

Similar Documents

Publication Publication Date Title
DK0637959T3 (da) Opløselige probucolanaloger
DE3260918D1 (en) Improved system for the determination of glucose in fluids
BR9801509A (pt) Vaso de reação, tira de teste, processos para conduzir uma reação de amplificação de ácido nucleico e para transferir um lìquido para dentro de umvaso de reação e estação de amoplificação de ácido nucleico para uma tira de teste.
ATE289874T1 (de) Station zur nukleinsäurevervielfältigung für wegwerftestträger
AU3595695A (en) Highly stable oxidative coupling dye for spectrophotometric determination of analytes
DK383683D0 (da) Apparat og fremgangsmade for kemisk dampafsaetning
FR2391185A1 (fr) Procede de preparation d'ether-carboxylates
IT7919741A0 (it) Dispositivo per la diffusione di sostanze fra due fluidi con temperatura simultanea di almeno uno dei detti fluidi.
KR870002280A (ko) 워킹비임(Walking Beam)형 재가열로(再加熱爐)
GB2020424A (en) Determination of glucose
NO142590C (no) Kontaktlegeme for vaeske og gass, saerlig for luftfuktere og kjoeletaarn.
GB1509693A (en) Immersion sampler for molten metal
EP0251195A3 (en) Method and reagent for the determination of alpha-amylase
EP0388144A3 (de) Reaktor für Reagenzien
EP0400965A3 (de) Reaktor zur chemischen Analyse
GB8423636D0 (en) Analytical solutions
ZA906998B (en) Process and reagent for the specific determination of pancreatic alpha-amylase
IT8567141A1 (it) Procedimento per le coltura di cellule, mediante dispersione di gas.
AU585472B2 (en) Chromogenic acridinone enzyme substrates
CN211131321U (zh) 一种用于取卵手术中试管的保温通气装置
NO168444C (no) Fremgangsmaate for fremstilling av en stabil, naturlig matriks til anvendelse ved immunologisk paavisning av psa
GR74999B (de)
SU1450589A1 (ru) Устройство для дифференциально-термического анализа
DK416285A (da) Fremgangsmaade til fremstilling af 0-alkyl-s-(alfa-forgrenet alkyl)alkylphosphono-thioater
NO153101C (no) Fremgangsmaate til fremstilling av jodmetyltiocyanat